Podoplanin (PDPN) is expressed in type I alveolar cells of lung but not in type II alveolar cells. PDPN is also known as a specific lymphatic endothelial cell marker because PDPN is not expressed in vascular endothelial cells. PDPNs of several animals have been characterized using specific anti-PDPN monoclonal antibodies (mAbs): PMab-1, PMab-2, PMab-32, PMab-38, PMab-44, and PMab-52 for mouse, rat, rabbit, dog, bovine, and cat PDPNs, respectively. In this study, we investigated the possible crossreaction between these anti-PDPN mAbs and tiger PDPN. Flow cytometry and western blot analyses revealed that the anti-cat PDPN mAb PMab-52 (IgM, kappa) reacted with tiger PDPN, which is overexpressed in Chinese hamster ovary-K1 cells. Using immunohistochemical analysis, type I alveolar cells of the tiger lung were strongly detected by PMab-52. These results indicate that PMab-52 may be useful for the detection of tiger PDPN.
Get full access to this article
View all access options for this article.
References
1.
Breiteneder-GeleffS, SoleimanA, KowalskiH, HorvatR, AmannG, KriehuberE, DiemK, WeningerW, TschachlerE, AlitaloK, and KerjaschkiD: Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: Podoplanin as a specific marker for lymphatic endothelium. Am J Pathol, 1999; 154:385–394.
2.
KatoY, FujitaN, KunitaA, SatoS, KanekoM, OsawaM, and TsuruoT: Molecular identification of Aggrus/T1alpha as a platelet aggregation-inducing factor expressed in colorectal tumors. J Biol Chem, 2003; 278:51599–51605.
3.
KajiC, TsujimotoY, Kato KanekoM, KatoY, and SawaY: Immunohistochemical examination of novel rat monoclonal antibodies against mouse and human podoplanin. Acta Histochem Cytochem, 2012; 45:227–237.
4.
OkiH, HonmaR, OgasawaraS, FujiiY, LiuX, TakagiM, KanekoMK, and KatoY: Development of sensitive monoclonal antibody PMab-2 against rat podoplanin. Monoclon Antib Immunodiagn Immunother, 2015; 34:396–403.
5.
HonmaR, FujiiY, OgasawaraS, OkiH, LiuX, NakamuraT, KanekoMK, TakagiM, and KatoY: Establishment of a novel monoclonal antibody PMab-32 against rabbit podoplanin. Monoclon Antib Immunodiagn Immunother, 2016; 35:41–47.
6.
HonmaR, KanekoMK, OgasawaraS, FujiiY, KonnaiS, TakagiM, and KatoY: Specific detection of dog podoplanin expressed in renal glomerulus by a novel monoclonal antibody PMab-38 in immunohistochemistry. Monoclon Antib Immunodiagn Immunother, 2016; 35:212–216.
7.
YamadaS, ItaiS, KanekoMK, and KatoY: PMab-48 recognizes dog podoplanin of lymphatic endothelial cells. Monoclon Antib Immunodiagn Immunother, 2018; 37:63–66.
KatoY, and KanekoMK: A cancer-specific monoclonal antibody recognizes the aberrantly glycosylated podoplanin. Sci Rep, 2014; 4:5924.
11.
KatoY, KunitaA, AbeS, OgasawaraS, FujiiY, OkiH, FukayamaM, NishiokaY, and KanekoMK: The chimeric antibody chLpMab-7 targeting human podoplanin suppresses pulmonary metastasis via ADCC and CDC rather than via its neutralizing activity. Oncotarget, 2015; 6:36003–36018.
12.
OgasawaraS, OkiH, KanekoMK, HozumiY, LiuX, HonmaR, FujiiY, NakamuraT, GotoK, TakagiM, and KatoY: Development of monoclonal antibody LpMab-10 recognizing non-glycosylated PLAG1/2 domain including Thr34 of human podoplanin. Monoclon Antib Immunodiagn Immunother, 2015; 34:318–326.
13.
OgasawaraS, KanekoMK, HonmaR, OkiH, FujiiY, TakagiM, SuzukiH, and KatoY: Establishment of mouse monoclonal antibody LpMab-13 against human podoplanin. Monoclon Antib Immunodiagn Immunother, 2016; 35:155–162.
14.
KatoY, OgasawaraS, OkiH, HonmaR, TakagiM, FujiiY, NakamuraT, SaidohN, KannoH, UmetsuM, KamataS, KuboH, YamadaM, SawaY, MoritaK, HaradaH, SuzukiH, and KanekoMK: Novel monoclonal antibody LpMab-17 developed by CasMab technology distinguishes human podoplanin from monkey podoplanin. Monoclon Antib Immunodiagn Immunother, 2016; 35:109–116.
15.
KatoY, OgasawaraS, OkiH, GoichbergP, HonmaR, FujiiY, and KanekoMK: LpMab-12 established by CasMab technology specifically detects sialylated O-glycan on Thr52 of platelet aggregation-stimulating domain of human podoplanin. PLoS One, 2016; 11:e0152912.
16.
OgasawaraS, KanekoMK, and KatoY: LpMab-19 recognizes sialylated O-glycan on Thr76 of human podoplanin. Monoclon Antib Immunodiagn Immunother, 2016; 35:245–253.
17.
KanekoMK, NakamuraT, HonmaR, OgasawaraS, FujiiY, AbeS, TakagiM, HaradaH, SuzukiH, NishiokaY, and KatoY: Development and characterization of anti-glycopeptide monoclonal antibodies against human podoplanin, using glycan-deficient cell lines generated by CRISPR/Cas9 and TALEN. Cancer Med, 2017; 6:382–396.
18.
KatoY, KunitaA, FukayamaM, AbeS, NishiokaY, UchidaH, TaharaH, YamadaS, YanakaM, NakamuraT, SaidohN, YoshidaK, FujiiY, HonmaR, TakagiM, OgasawaraS, MurataT, and KanekoMK: Antiglycopeptide mouse monoclonal antibody LpMab-21 exerts antitumor activity against human podoplanin through antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. Monoclon Antib Immunodiagn Immunother, 2017; 36:20–24.
19.
KanekoMK, YamadaS, NakamuraT, AbeS, NishiokaY, KunitaA, FukayamaM, FujiiY, OgasawaraS, and KatoY: Antitumor activity of chLpMab-2, a human–mouse chimeric cancer-specific antihuman podoplanin antibody, via antibody-dependent cellular cytotoxicity. Cancer Med, 2017; 6:768–777.
20.
YamadaS, KanekoMK, and KatoY: LpMab-23: A cancer-specific monoclonal antibody against human podoplanin. Monoclon Antib Immunodiagn Immunother, 2017; 36:72–76.
KatoY, KanekoMK, KunitaA, ItoH, KameyamaA, OgasawaraS, MatsuuraN, HasegawaY, Suzuki-InoueK, InoueO, OzakiY, and NarimatsuH: Molecular analysis of the pathophysiological binding of the platelet aggregation-inducing factor podoplanin to the C-type lectin-like receptor CLEC-2. Cancer Sci, 2008; 99:54–61.
23.
KanekoM, KatoY, KunitaA, FujitaN, TsuruoT, and OsawaM: Functional sialylated O-glycan to platelet aggregation on Aggrus (T1alpha/podoplanin) molecules expressed in Chinese Hamster Ovary cells. J Biol Chem, 2004; 279:38838–38843.
24.
KanekoMK, KatoY, KitanoT, and OsawaM: Conservation of a platelet activating domain of Aggrus/podoplanin as a platelet aggregation-inducing factor. Gene, 2006; 378:52–57.
25.
SekiguchiT, TakemotoA, TakagiS, TakatoriK, SatoS, TakamiM, and FujitaN: Targeting a novel domain in podoplanin for inhibiting platelet-mediated tumor metastasis. Oncotarget, 2015; 7:3934–3946.
26.
MiyazakiA, NakaiH, SonodaT, HirohashiY, KanekoMK, KatoY, SawaY, and HiratsukaH: LpMab-23-recognizing cancer-type podoplanin is a novel predictor for a poor prognosis of early stage tongue cancer. Oncotarget, 2018; 9:21156–21165.
27.
AkinEY, BaumgartnerWA, LeeJK, and BeasleyMJ: Meningioma in a Bengal tiger (Panthera tigris tigris). J Zoo Wildl Med, 2013; 44:761–764.
28.
KangMS, ParkMS, KwonSW, MaSA, ChoDY, KimDY, and KimY: Amyloid-producing odontogenic tumour (calcifying epithelial odontogenic tumour) in the mandible of a Bengal tiger (Panthera tigris tigris). J Comp Pathol, 2006; 134:236–240.
29.
PoweJ, CastlemanW, and FiorelloC: A thymic carcinoid in a Bengal tiger (Panthera tigris). J Zoo Wildl Med, 2005; 36:531–533.
30.
ScudamoreCL, and MeredithAL: Sertoli cell tumour in an Amur tiger. J Comp Pathol, 2001; 124:79–82.
31.
ShiltonCM, ThompsonMS, MeisnerR, LockB, and LindsayWA: Nasopharyngeal myxosarcoma in a Bengal tiger (Panthera tigris). J Zoo Wildl Med, 2002; 33:371–377.
32.
SteinmetzHW, RuttenM, Ruess-MelzerK, OhlerthS, LischerC, OevermannA, Bode-LesniewskaB, and HattJM: Clinical course of a malignant peripheral nerve sheath tumor in a Siberian tiger (Panthera tigris altaica). J Vet Diagn Invest, 2010; 22:970–975.
33.
WiednerEB, IsazaR, LindsayWA, CaseAL, DeckerJ, and RobertsJ: Pericardial mesothelioma in a Bengal tiger (Panthera tigris). J Zoo Wildl Med, 2008; 39:121–123.
34.
ItaiS, YamadaS, KanekoMK, HaradaH, KagawaY, KonnaiS, and KatoY: Expression of cat podoplanin in feline squamous cell carcinomas. Monoclon Antib Immunodiagn Immunother, 2017; 36:243–250.
35.
ChangYW, KanekoMK, YamadaS, and KatoY: Epitope mapping of monoclonal antibody PMab-52 against cat podoplanin. Monoclon Antib Immunodiagn Immunother, 2018; 37:95–99.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
